Paper Details

  1. Home
  2. Paper Details

Pegylated interferon alfa-2b (peg-intron) plus ribavirin (rebetol) in the treatment of chronic hepatitis C: a local experience.

Author: Robert DingP H, SeowE L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pegylated interferon alfa-2b plus ribavirin was found to be efficacious and safe in treating chronic hepatitis C, with a sustained virological response of 39.10% in naïve patients.
Paper Details　
Original Abstract of the Article :
This was an open-label, uncontrolled study with the aim of assessing the efficacy and safety of pegylated interferon alfa-2b plus ribavirin in the treatment of chronic hepatitis C. The study was conducted in Island Hospital, Penang beween January 2002 and December 2003. Thirty-three patients were en...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/16515116

データ提供：米国国立医学図書館（NLM）

Pegylated Interferon Alfa-2b: A New Oasis in the Desert of Hepatitis C Treatment

Hepatitis C, a chronic liver infection, can be a challenging foe, like a relentless desert sandstorm that erodes the body's vital organs. This study investigates the efficacy and safety of pegylated interferon alfa-2b plus ribavirin in treating chronic hepatitis C. The researchers are like skilled desert navigators, seeking to find a safe and effective path to recovery.

Exploring the Effectiveness of Treatment

The study found that the combination of pegylated interferon alfa-2b and ribavirin was effective in achieving a sustained virological response (SVR) in a significant proportion of patients. The researchers observed tolerable side effects, with anemia being the most common. It's like finding a reliable oasis in the desert, providing sustenance and a chance for recovery.

A Glimmer of Hope in the Fight Against Hepatitis C

This study offers a glimmer of hope for individuals battling chronic hepatitis C. The findings suggest that pegylated interferon alfa-2b plus ribavirin could be a valuable tool in the fight against this challenging disease. It's like discovering a new source of water in a parched desert, offering the potential for a more sustainable and healthy future.

Dr. Camel's Conclusion

This research provides valuable insights into the effectiveness and safety of pegylated interferon alfa-2b plus ribavirin in treating chronic hepatitis C. The findings suggest that this treatment could be a valuable option for individuals seeking to combat this challenging disease. It's like finding a path through the desert that leads to a destination of better health and well-being.

Date :
  1. Date Completed 2006-04-11
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

16515116

DOI: Digital Object Identifier

16515116

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.